CLYM
Climb Bio, Inc. NASDAQ$9.69
Mkt Cap $660.7M
52w Low $1.13
95.4% of range
52w High $10.10
50d MA $7.59
200d MA $3.98
P/E (TTM)
-10.1x
EV/EBITDA
-3.5x
P/B
3.8x
Debt/Equity
0.0x
ROE
-37.3%
P/FCF
-5.0x
RSI (14)
—
ATR (14)
—
Beta
-0.20
50d MA
$7.59
200d MA
$3.98
Avg Volume
570.8K
About
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its nam…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.20 | -0.26 | -30.0% | 7.39 | -0.4% | -2.8% | -1.9% | -0.8% | -0.8% | -1.8% | — |
| Nov 6, 2025 | AMC | -0.16 | -0.19 | -18.8% | 1.95 | -3.1% | -6.2% | -7.7% | -2.6% | -1.5% | -4.1% | — |
| Aug 12, 2025 | AMC | -0.19 | -0.13 | +31.6% | 1.61 | +2.5% | +1.2% | +6.8% | +18.0% | +31.1% | +25.5% | — |
| May 14, 2025 | AMC | -0.15 | -0.31 | -106.7% | 1.17 | +0.0% | +2.6% | +10.3% | +8.5% | +6.0% | +3.4% | — |
| Mar 25, 2025 | AMC | -0.15 | -0.13 | +13.3% | 1.30 | +3.1% | +0.0% | -2.3% | -1.5% | -6.2% | -7.7% | — |
| Nov 12, 2024 | AMC | — | -0.13 | — | 3.80 | +6.3% | -7.1% | -15.8% | -20.8% | -19.5% | -14.5% | — |
| Aug 14, 2024 | AMC | — | -1.81 | — | — | — | — | — | — | — | — | — |
| May 15, 2024 | AMC | — | -0.06 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | -0.13 | -0.13 | -2.5% | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | -0.14 | -0.15 | -4.7% | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5 | Chardan Capital Markets | Initiates | Buy | $22 | — | — | — | — | — | — | — | — |
| Apr 21 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.97 | $9.24 | +3.0% | +4.5% | +3.7% | +0.6% | +1.9% | +5.9% |
| Apr 8 | BTIG | Maintains | Buy → Buy | — | $6.87 | $7.10 | +3.3% | +3.3% | +17.2% | +22.4% | +25.6% | +28.8% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.25 | $7.48 | +3.2% | +1.1% | +1.1% | +0.1% | -3.0% | -1.7% |
| Mar 6 | Baird | Maintains | Outperform → Outperform | — | $7.39 | $7.36 | -0.4% | -2.8% | -1.9% | -0.8% | -0.8% | -1.8% |
| Mar 6 | Wedbush | Maintains | Outperform → Outperform | — | $7.39 | $7.36 | -0.4% | -2.8% | -1.9% | -0.8% | -0.8% | -1.8% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.25 | $4.33 | +1.9% | +3.1% | +0.7% | +15.3% | +8.2% | +14.1% |
| Oct 16 | BTIG | Maintains | Buy → Buy | — | $1.94 | $2.06 | +6.2% | +0.5% | -0.5% | +19.6% | +16.5% | +6.2% |
| Sep 30 | BTIG | Maintains | Buy → Buy | — | $1.99 | $1.99 | +0.0% | +1.0% | -1.0% | +2.5% | -0.5% | -9.0% |
| Sep 22 | BTIG | Maintains | Buy → Buy | — | $2.31 | $2.42 | +4.8% | +0.4% | -2.6% | -5.2% | -9.1% | -7.8% |
Recent Filings
8-K · 7.01
! Medium
Climb Bio, Inc. -- 8-K 7.01: Regulation FD Disclosure
Climb Bio disclosed investor event materials via webcast and presentation, providing shareholders access to updated company information and strategic messaging through its website.
May 5
8-K · 1.01
! Medium
Climb Bio, Inc. -- 8-K 1.01: Equity Issuance
Climb Bio raised $110 million through an equity issuance, strengthening its balance sheet for clinical development and operations.
Apr 28
8-K
Unknown — 8-K Filing
Tiffany Altschuller's appointment as Head of Investor Relations brings relevant biotech finance and IR experience to CLYM, potentially improving capital markets communication and shareholder engagement.
Apr 3
8-K
Climb Bio, Inc. -- 8-K Filing
Climb Bio (CLYM) advanced its immune-disease therapeutic pipeline throughout 2025 while maintaining disciplined execution, indicating progress toward clinical development goals for investors.
Mar 5
Data updated apr 25, 2026 1:52am
· Source: massive.com